𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gefitinib plus docetaxel in non-small-cell lung cancer

✍ Scribed by Gérard Zalcman; Emmanuel Bergot

Book ID
117304331
Publisher
The Lancet
Year
2009
Tongue
English
Weight
71 KB
Volume
373
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib versus cisplatin plus docetaxe
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
✍ Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamot 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 239 KB

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by